跳至主要内容
临床试验/NCT04577846
NCT04577846Unknown3 期

Surgical Site Infection (SSI) Rates in Patients Undergoing Mastectomy Without Reconstruction, a Comparison Among Those Receiving Preoperative Prophylactic Antibiotics Alone Versus Continued Prophylactic Antibiotics Postoperatively-A Multicenter, Double-blinded Randomized Control Trial.

Aga Khan University3 个研究点 分布在 1 个国家目标入组 384 人开始时间: 2020年11月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
入组人数
384
试验地点
3
主要终点
Surgical Site Infection (SSI)

研究概览

简要总结

Breast cancer is the second most prevalent malignancy in the world and an important component of treatment warrants surgical procedures such as mastectomy. Surgical site infections after breast surgery may range from 1-26%, which is high for surgeries that are considered "clean procedures", as defined by the Centers for Disease Control and Prevention (CDC) wound classification system.

Prophylactic antibiotics given before the surgical incision as per Joint Commissions SCIP (Surgical Care Improvement Project) guidelines, have been shown to decrease the rate of postoperative infections in a vast number of patients. There is however, no clear consensus due to lack of evidence on continuation (duration) of prophylactic antibiotics in patients undergoing mastectomy with indwelling drains, and thus antibiotic prescribing practices may vary among breast as well as reconstructive surgeons.

In this trial all patients undergoing mastectomy without immediate reconstruction will receive a single prophylactic dose of preoperative antibiotic, and subsequently, the patients will be randomized to either continue the prophylactic antibiotics or receive a placebo for the duration of indwelling drains. The aim of this trial is to compare the difference in SSI rates between these two study arms as the main outcome. In addition, the factors associated with differing rates of SSI in the intervention and control group will also be identified.

详细描述

Introduction:

Worldwide, breast cancer comprises 10.4% of all cancer among women, making it the second most common cancer (after lung cancer) and the fifth most common cause of cancer related death. The management of patients as a matter of patient preference or as dictated by extent of disease often warrants a mastectomy.

Reports of surgical site infections after breast surgery including mastectomy may range from 1-26%, which is high for surgeries that are considered "clean procedures". Despite a high rate of surgical site infections, there is no consensus on the continuation/duration of prophylactic antibiotics in patients undergoing mastectomy. Consequently, practices may vary among breast and reconstructive surgeons. Evidence regarding the risk of SSI with the use and duration of indwelling drains is also controversial. The length of prolonged, postoperative antibiotic may also vary by practitioners, some using a pre-defined regimen of about 2-7 days, and others continuing them until the drains are removed.

Most guidelines recommend a single dose of pre-operative antibiotics and continuation after surgery has been discouraged. The use of common or more specific antibiotics for the duration of drains being in place is also controversial. The recommendation by recent national clinical guidelines is to use one dose of pre-procedural antibiotics for mastectomy patients with or without drains. The American Society of Breast Surgeons also does not recommend the continuation of post-surgical antibiotics in the absence of relevant indications. However, practices vary.

Rationale:

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Patients who will undergo mastectomy (without immediate reconstruction) at AKUH, LNH, and DUHS (with or without axillary surgery), who will have indwelling closed suction drain(s) postoperatively and will give consent to participate in the study

排除标准

  • Undergo breast reconstruction
  • Who have other medical indications for which they must remain on antibiotics for more than the single preoperative dose
  • Those with any history of allergies to beta-lactam drug
  • Patients who had an open breast or axillary biopsy/breast conservation in the last 30 days on the ipsilateral side.

研究组 & 干预措施

Intervention Arm

Active Comparator

The intervention arm will be administered, either Cefazolin iv every 8 hours while NPO or cefalexin 500 mg q8 hours per oral if tolerating a diet.

干预措施: Cephalexin 500 MG (Drug)

Control

Placebo Comparator

Controls will be provided with initially IV placebo while NPO and then with a placebo capsule filled with inert material for the duration of the drains which usually is about 14 days.

干预措施: Placebo (Drug)

结局指标

主要结局

Surgical Site Infection (SSI)

时间窗: up to 30 days.

Standard CDC criteria: 1. purulent drainage from the incision or drain site; 2. organisms isolated from an aseptically obtained culture of fluid or tissue; 3. deliberate opening of the incision by a surgeon in patients having either tenderness, localized swelling, redness, or warmth; or 4. diagnosis of SSI by the surgeon or study wound assessor or 5. prescription of therapeutic antibiotics; 6. Patients clinically diagnosed and documented to have cellulitis.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Abida K. Sattar, MD, FACS

Assistant Professor and Section Head

Aga Khan University

研究点 (3)

Loading locations...

相似试验

SSI Rates in Patients Undergoing Mastectomy Without... | 临床试验